Core Viewpoint - Chuangsheng Group (stock code: 6628) announced a new share placement to raise approximately HKD 62.4 million, with net proceeds expected to be around HKD 59.3 million after expenses [1] Group 1: Financing Details - The company plans to issue 14,400,000 new shares at a placement price of HKD 4.33, representing a discount of about 18.8% to the previous trading day's closing price of HKD 5.33 [1] - The placement price also reflects a discount of approximately 13.6% compared to the average closing price over the last five trading days [1] - The new shares will account for about 3.3% of the existing issued share capital and approximately 3.2% of the enlarged share capital post-issue [1] Group 2: Use of Proceeds - Approximately HKD 23.7 million will be allocated for the clinical development of pipeline assets TST001 and TST002 [1] - Around HKD 17.8 million is designated for advancing promising preclinical pipeline assets with potential for external licensing in the near term [1] - Another HKD 17.8 million will be used for working capital and general purposes [1] Group 3: Transaction Timeline - The issuance is based on a general authorization granted at the shareholders' meeting and is expected to be completed by September 17, 2025 [1]
创胜集团 ：通过一般授权配售新股募资约 6240 万港元 药物研发及运营资金补充